CEMAG Care mission is to answer patients’ medical needs by developing and commercializing innovative medical devices and drugs by allowing access of these treatments to populations in need.
To achieve this mission, we foster innovative healthcare research projects into viable commercial products (drugs, medtech, biotech) and bring them to patients. Our motivation is to answer meaningful unmet medical needs and bring to all patients the care they deserve.
Development and commercialization of healthcare innovation:
Fostering the development and the commercialization of healthcare innovations such as medical devices or in vitro diagnostics
Specific activity toward Non-For-Profit Organizations to facilitate medical product accessibility to population in need
Pharmaceutical operations of various pharmaceutical products in France (“Exploitant Pharmaceutique”, MAH) and other European countries:
> Market Authorization Holder and distribution of pharmaceutical products
> Regulatory (submissions, applications and regulatory Life Cycle Management activities….)
> Medical Affairs (pharmacovigilance, medical information, clinical studies, scientific advice, Literature reviews, medical writing…)
> Service activities for third parties for regulatory strategy and registration in Europe
> A senior team with high expertise and a history of success stories
> Exploitant of Marketing Authorisations in France
In compliance with article L.5121-1-3 of French Public Health Code (Code de la Santé Publique), please find below the list of all active substances of drug products exploited by Cemag Care :
LIST OF DRUG PRODUCTS EXPLOITED BY CEMAG CARE
For medical information request or pharmacovigilance, please contact pharmacovigilance@cemagcare.com
> Product development in accordance with ISO13485: from initial patient needs to breakthrough medical solutions.
> Fostering our own projects of medical devices
> Providing service activities to help the development of innovative medical solutions (from Proof of Concept Studies to Market authorization
> Materiovigilance
> An expertized team focused on innovation for patients
In healthcare, all patients are entitled to all approved products with the highest quality standards.
> Facilitating relationship between For-Profit Healthcare industry and Non-For-Profit Organizations, to allow :
> Populations in needs to access healthcare products
> Healthcare companies to develop new markets and increase their product volumes
> Supplier for Pharma industries dedicated to Non-For-Profit and Public markets (handling of tenders, agreements, logistics)
> Strong network with Non-For-Profit Organizations
ANDRÉ ULMANN
MD, PhD
Founder
and CEO
JEAN-FRANCOIS LE MEUR
Regulatory Affairs Specialist
STÉPHANIE LE CORRE
Quality Affairs Manager
MAÏA ALEXALINE – PhD
Scientific Director
ANAÏS CASTIGLIA
Marketing Manager
VICTORIA MICHAELS LOPEZ
PhD
Project Manager
CLÉMENCE DESJARDIN – PhD
Project Manager
MANON EXPOSITO – Pharm.D.
Pharmaceutical Affairs Director
QPPV
Qualified Person
MARIE CROIZAT – Pharm.D.
Regulatory Affairs Director
PATRICK GAUDE – Pharm.D.
Technical Director
AMEL ABBES
Office Manager
> Dermatology & Wound care
> Women’s health (innovative fertility regulation methods)
> Diagnostic
> Emergency healthcare (e.g. bioterrorism)
> Antivenoms and antitoxins
> Orphan Diseases
> Addiction
March 2019
Cemag Care is MAH of CURETHYL 26 POUR CENT, solution injectable I.V, CALPRIMUM 500 mg, comprimé enrobé à croquer, and ASCOFER 33 mg, gélule
March 2017
André Ulmann’s book « Le combat d’un médecin pour les femmes » has just been published (French edition only for the moment).
